Parkman Healthcare Partners LLC Has $11.67 Million Stock Holdings in CVRx, Inc. (NASDAQ:CVRX)

Parkman Healthcare Partners LLC lifted its holdings in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 34.9% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 921,174 shares of the company's stock after buying an additional 238,277 shares during the period. CVRx makes up approximately 1.6% of Parkman Healthcare Partners LLC's portfolio, making the stock its 23rd biggest holding. Parkman Healthcare Partners LLC owned 3.80% of CVRx worth $11,671,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its position in shares of CVRx by 10,520.1% in the 4th quarter. JPMorgan Chase & Co. now owns 628,286 shares of the company's stock worth $7,960,000 after purchasing an additional 622,370 shares in the last quarter. Emerald Advisers LLC increased its stake in shares of CVRx by 47.3% in the 4th quarter. Emerald Advisers LLC now owns 593,898 shares of the company's stock worth $7,525,000 after purchasing an additional 190,844 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its holdings in CVRx by 28.8% in the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 370,813 shares of the company's stock worth $4,698,000 after acquiring an additional 82,978 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of CVRx by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 323,931 shares of the company's stock worth $4,105,000 after acquiring an additional 28,807 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of CVRx by 4.3% during the 4th quarter. Northern Trust Corp now owns 138,883 shares of the company's stock valued at $1,760,000 after purchasing an additional 5,671 shares during the last quarter. Institutional investors own 75.27% of the company's stock.

CVRx Trading Up 14.5%

NASDAQ CVRX opened at $5.44 on Wednesday. The company's fifty day simple moving average is $9.01 and its 200-day simple moving average is $12.53. CVRx, Inc. has a 52 week low of $4.30 and a 52 week high of $18.55. The stock has a market cap of $141.75 million, a P/E ratio of -2.02 and a beta of 1.39. The company has a current ratio of 12.06, a quick ratio of 10.23 and a debt-to-equity ratio of 0.69.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.03. CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. The company had revenue of $12.35 million for the quarter, compared to analyst estimates of $14.68 million. Equities research analysts predict that CVRx, Inc. will post -1.91 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on CVRX shares. Craig Hallum increased their price target on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, January 17th. JPMorgan Chase & Co. restated an "underweight" rating and set a $7.00 target price (down from $15.00) on shares of CVRx in a research report on Friday, May 9th. William Blair upgraded CVRx from a "market perform" rating to an "outperform" rating in a research report on Tuesday, January 14th. Canaccord Genuity Group dropped their target price on CVRx from $23.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, April 8th. Finally, Piper Sandler dropped their target price on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $14.50.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.